Nobio Overview
Nobio develops long-term antibacterial and antiviral solutions for medical, dental, and consumer products. The company commercializes its antimicrobial technology both through its own products and through partnerships with industry leaders. Nobios core technology consists of extremely potent particles covered with a high concentration of highly active antimicrobial molecules that kill a wide range of microorganisms (bacteria, viruses, fungi, etc.) on contact. The Nobio particles can be permanently embedded in, or used as a coating on, many products and materials, providing powerful bioprotection for life. In September 2019, the company received FDA approval to market Infinix, its line of antibacterial products for dental fillings. In response to COVID-19, Nobio is also implementing its technology in personal protective equipment (PPE) and surface coatings. Nobio is working with several industry leaders to incorporate its technology into their medical, dental, and consumer products. Nobio also received a grant from the Israeli Innovation Authority for its work on PPE and is involved in discussions with potential partners for commercialization.
Cumulative Funding Raised Over Time ($)
$3.6MAug 2018
$3.6MJan 2021
Latest News
growth-positive
Nobio's infinix™ Antibacterial Composites Recognized as a 2021 Best of Class Technology Award Winner
Nobio Ltd., the inventor of FDA cleared antibacterial composites, has been recognized as a 2021 Best of Class Technology Award winner for its infinix line of advanced restorative materials. The award highlights the clinical importance of infinix in preventing demineralization and reducing restoration failure due to secondary caries. The infinix line includes various composites and a bonding system, all incorporating Nobios patented antimicrobial particle technology. The recognition from the panel of thought-leading clinicians signifies the promise of the Nobio platform. Nobio is a material sciences company that aims to bring long-lasting antimicrobial properties to a wide range of products and applications. The article does not mention any specific partners, investors, customers, or financial details.
Partners
growth-positive
Nobio's Antibacterial Composites Receive FDA 510(k) Clearance for Addressing a Key Process in Tooth Decay
Nobio Ltd. has received FDA 510(k) clearance for its Infinix family of dental composites. Clinical data showed that the composites significantly reduce tooth demineralization, a key process in tooth decay. The composites incorporate Nobios patented QASiTM particle technology, which inhibits bacterial growth at the margins of composite fillings. The company plans to initiate commercial sales of the Infinix product line by the end of the year. The article highlights the potential for Infinix to reduce recurrent decay, improve restoration longevity, and minimize natural tooth loss. The FDA clearance validates the technology and its potential impact on restorative dentistry.
Customers
growth-positive
Nobio Secures Grant From the Israel Innovation Authority for Protective Measures Against Covid-19
Nobio Ltd. has received a grant from the Israel Innovation Authority to develop and manufacture innovative solutions for managing the COVID-19 outbreak. The $205,000 grant will support the development and manufacture of personal protective equipment (PPE) and long-acting surface coating using Nobios antimicrobial technology. The companys Infinix products for dental restorations received FDA clearance last year and will be launched commercially in the second half of 2020. The grant will focus on two applications: antiviral facemasks and nonwoven fabrics for protective wear, as well as surface coatings to prevent transmission of pathogenic microorganisms. Nobio is also scaling up production capacity to meet the expected increase in demand.
Investment
Nobio and Supergum to Prototype and Test Protective Face Masks Against Viruses
growth-positive
Startup Nobio gets FDA nod for antibacterial dental fillings
Israeli startup Nobio Ltd. has received FDA approval to market its antibacterial material for dental fillings. The approval gives Nobio access to the $1.4 billion dental materials market. The company plans to make its products available to dentists through its own brand and through licensing to other manufacturers. Nobio is currently negotiating with distributors and manufacturers for commercial partnerships. The FDA approval also increases the chances of further approvals for the companys technology. Nobio has raised $9 million to date from investors including aMoon Fund and Dr. Ole Jensen.
Customers
| Sector | Industrial Technologies |
Funding
| Total funding | $4M |
| Last funding | Undisclosed |
| Stage | B |
| Rounds | 4 |
| Investors | 2 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | www.nobio.com |
Locations
HaMatechet St 8, Kadima Zoran, Israel
Photos & Videos
3 item(s)
Nobio Business
Business models
B2B, B2B2C
Product stage
Released
Employees
11-50
Sector
Industrial TechnologiesMaterial Innovations & ApplicationsTarget Customer
Healthcare & Life SciencesHealthcareProvidersLaboratoriesIndustrial ManufacturingManufacturing FacilitiesCore Technology
BiologicalsMoleculesTags (17)
bioconvergencedentistspharmaceuticalsnanotechnologymedical-devicesdentalbiotechnologymaterialsmedical-equipmentmicrobiologypackaging-and-containerstextilemanufacturing-facilitieshygienesurface-and-coatingshvachospitalsGeographic Markets
GlobalNobio Financials
$4M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
B
Funding stage
4
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$3.6MAug 2018
$3.6MJan 2021
Private Equity Funding
B Round
Jan 2021
Undisclosed
A Round
Aug 2018
$3.6M
Dr. Ole Jensen, aMoon Fund
Non-Equity Funding
GrantEvent
Apr 2020
$205K
Israel Innovation Authority
GrantEvent
Nov 2016
$200K
Nobio Lifecycle
Cumulative Funding Raised Over Time
$3.6MAug 2018
$3.6MJan 2021
All Events
B Round
Jan 2021
Undisclosed
A Round
Aug 2018
$3.6M
Dr. Ole Jensen, aMoon Fund
GrantEvent
Apr 2020
$205K
Israel Innovation Authority
GrantEvent
Nov 2016
$200K
Nobio News
7 articles
growth-positive
Nobio's infinix™ Antibacterial Composites Recognized as a 2021 Best of Class Technology Award Winner
Nobio Ltd., the inventor of FDA cleared antibacterial composites, has been recognized as a 2021 Best of Class Technology Award winner for its infinix line of advanced restorative materials. The award highlights the clinical importance of infinix in preventing demineralization and reducing restoration failure due to secondary caries. The infinix line includes various composites and a bonding system, all incorporating Nobios patented antimicrobial particle technology. The recognition from the panel of thought-leading clinicians signifies the promise of the Nobio platform. Nobio is a material sciences company that aims to bring long-lasting antimicrobial properties to a wide range of products and applications. The article does not mention any specific partners, investors, customers, or financial details.
Partners
growth-positive
Nobio's Antibacterial Composites Receive FDA 510(k) Clearance for Addressing a Key Process in Tooth Decay
Nobio Ltd. has received FDA 510(k) clearance for its Infinix family of dental composites. Clinical data showed that the composites significantly reduce tooth demineralization, a key process in tooth decay. The composites incorporate Nobios patented QASiTM particle technology, which inhibits bacterial growth at the margins of composite fillings. The company plans to initiate commercial sales of the Infinix product line by the end of the year. The article highlights the potential for Infinix to reduce recurrent decay, improve restoration longevity, and minimize natural tooth loss. The FDA clearance validates the technology and its potential impact on restorative dentistry.
Customers
growth-positive
Nobio Secures Grant From the Israel Innovation Authority for Protective Measures Against Covid-19
Nobio Ltd. has received a grant from the Israel Innovation Authority to develop and manufacture innovative solutions for managing the COVID-19 outbreak. The $205,000 grant will support the development and manufacture of personal protective equipment (PPE) and long-acting surface coating using Nobios antimicrobial technology. The companys Infinix products for dental restorations received FDA clearance last year and will be launched commercially in the second half of 2020. The grant will focus on two applications: antiviral facemasks and nonwoven fabrics for protective wear, as well as surface coatings to prevent transmission of pathogenic microorganisms. Nobio is also scaling up production capacity to meet the expected increase in demand.
Investment
Nobio and Supergum to Prototype and Test Protective Face Masks Against Viruses
growth-positive
Startup Nobio gets FDA nod for antibacterial dental fillings
Israeli startup Nobio Ltd. has received FDA approval to market its antibacterial material for dental fillings. The approval gives Nobio access to the $1.4 billion dental materials market. The company plans to make its products available to dentists through its own brand and through licensing to other manufacturers. Nobio is currently negotiating with distributors and manufacturers for commercial partnerships. The FDA approval also increases the chances of further approvals for the companys technology. Nobio has raised $9 million to date from investors including aMoon Fund and Dr. Ole Jensen.
Customers
growth-positive
Bacteria resistant materials co Nobio raises $3.6m
Israeli company Nobio has raised $3.5 million in a financing round led by aMoon fund and anchor investor Marius Nacht. Nobio develops bacteria-resistant materials for the medical devices and dental health markets. Their lead product is a material for dental fillings that prevents infection. The company plans to obtain marketing approval for this product in 2019 and hopes to include it in a variety of medical devices. Nobios technology integrates bacteria-killing particles within the material using nanotechnology production technology. The investment will enable the company to obtain regulatory approvals and make progress in trials of medical applications.
InvestmentExpand
growth-positive
Germs are no match for NanoLock's antimicrobial nanomaterial
Israeli company NanoLock expects to win regulatory clearance for its first two products embedded with a novel antimicrobial nanomaterial. The nanomaterial, developed by Prof. Ervin Weiss, has the potential to address biofilm-related infections on medical devices. NanoLocks first priority is dental materials, but the company is open to strategic partnerships to expand into other fields. The nanomaterial is unique in that it kills both bacteria and fungi, is built into the device, and contains no metal or toxic ingredients. NanoLock is completing a feasibility study and is looking to complete its first investment round. The company aims to enable the use of medical devices with inherent antimicrobial properties throughout their lifecycle.
PartnersInvestment
Nobio Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 28 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 12 classification IDs that could be used for matching.
Nobio Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 515281285 |
| Crunchbase | nobio |
| Phone | +97297893000 |
| Creator | Jenny Sotnik-Talisman |
| Creator email | genys30@yahoo.com |
| Last updater | Maor Perlov |
| Updater email | maor.perlov@sncentral.org |
| Last update | 2022-10-06T00:00:00.000Z |
| Created | 2017-12-25T00:00:00.000Z |